Floatz logo

Siremadlin

High-risk Myelodysplastic Syndrome (MDS)

Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
95/ 100

Competitive context

315 Active assets in the High-risk Myelodysplastic Syndrome (MDS) cohort.

Asset / SponsorPhaseRating
FILGRASTIM
City of Hope Medical Center
Phase 4BB
Fludarabine
Sawa Ito, MD
Phase 4BB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 4BB
Cyclophosphamide
Sawa Ito, MD
Phase 4BB
Anti-Thymoglobulin, Rabbit
Peking University First Hospital
Phase 2/3BB

View all 50 →

Same molecule, other indications

Siremadlin is also rated in:

Malignant Solid TumorDormant
CC
Indicative ·
46 / 100
View asset →
Allogeneic Stem Cell TransplantationDormant
CC
Indicative ·
43 / 100
View asset →
Advanced Solid and Hematological TP53wt TumorsDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →